ACHN News Alert Achillion Pharmaceuticals (ACHN) 10.23 11/05/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 5:53 AM

Achillion Pharmaceuticals (ACHN) 10.23 $ACHN

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.01 (-3.83), ALIM: 5.02 (-0.18), ACHN: 10.23 (-1.89), FNHC: 29.21 (-1.20), ARCP: 8.15 (+0.30), CKEC: 28.36 (-0.08), JAXB: 10.50 (+1.65), PCLN: 1,097.70 (-100.82), TESO: 15.84 (-2.67)

Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.76 (+1.88), PLUG: 5.35 (+0.21), NYMX: 0.82 (-0.11), INTC: 34.54 (+0.23), FOX: 31.99 (-1.12), SAPE: 24.66 (+0.06), GERN: 2.68 (-0.12), ACHN: 10.23 (-1.89), FOXA: 33.33 (-1.02), ODP: 6.33 (+1.26), ARCP: 8.15 (+0.30), MSFT: 47.57 (+0.13), GRPN: 7.84 (+0.47), AAPL: 108.60 (-0.80)

Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 10.23 (-1.89)

Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 89.99 (-2.57), CYTX: 0.48 (-0.01), ACHN: 10.23 (-1.89), INCY: 67.76 (-0.21), SRPT: 16.38 (-0.02)

Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 10.23 (-1.89)

Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 10.23 (-1.89)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)

Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 382.78 (-5.63), ACHN: 10.23 (-1.89), CVS: 85.47 (-0.65), N: 108.92 (+1.66), PAY: 37.35 (+0.16)

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)

Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 23.28 (-0.94), FBHS: 42.44 (-0.83), ACHN: 10.23 (-1.89), KBH: 15.69 (-0.30), HOV: 3.76 (-0.05)

November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 10.23 (-1.89)

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
GlobeNewswire - Wed Oct 08, 9:23AM CDT
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
ACHN: 10.23 (-1.89)

Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 108.62 (+1.16), SGEN: 36.57 (-0.68), CPRX: 2.97 (-0.06), ACHN: 10.23 (-1.89), SNSS: 1.68 (unch), BMY: 57.84 (+0.04)

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 01, 11:37AM CDT
Source: Achillion Pharmaceuticals. Achillion investors are probably shaking their heads wondering what's wrong with their company following Johnson & Johnson 's acquisition of the privately held Alios for $1.7 billion this week. On the...
JNJ: 108.62 (+1.16), GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89)

J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45)

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), NVAX: 5.55 (+0.03), ACHN: 10.23 (-1.89)

Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver
PR Newswire - Tue Sep 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, DWA, SUNE, LOCO and WFM.
WFM: 39.80 (-0.15), SUNE: 19.65 (-0.36), ACHN: 10.23 (-1.89), LOCO: 36.19 (+0.49), DWA: 21.92 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...